{
}
UBS Group has initiated coverage on Celldex Therapeutics (NASDAQ:CLDX) with a "buy" rating and a price target of $44.00, indicating a potential upside of 97.66%. The stock currently holds a "Moderate Buy" consensus rating, with an average price target of $60.22 from various analysts. Celldex, a biopharmaceutical company, focuses on developing therapeutic antibodies for various diseases, and has seen significant institutional investment recently.
Celldex has been initiated with a Buy rating by UBS, indicating positive expectations for the company's performance in the market. This recommendation highlights the potential for growth and investment opportunities within Celldex.
Evommune, a California biotech startup, has secured $115 million in Series C funding to advance its immune drug candidates, EVO756 and EVO301, targeting chronic immune conditions. The funding will support three Phase 2 trials, with results expected by the end of 2026. EVO756, an oral treatment for chronic skin hives, aims to be a first-in-class therapy, while EVO301 targets atopic dermatitis and shows promise in early testing.
Celldex Therapeutics, Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
analysts recommend five stocks over celldex therapeutics for investment opportunities
14:23 14.02.2025
Celldex receives buy rating from UBS according to market report
13:55 13.02.2025
Evommune secures 115 million dollars to advance immune drug development
United States Dollar
Regeneron Pharmaceuticals, Inc.
Incyte Corporation
Novartis AG
Celldex Therapeutics, Inc.
Sanofi
USA
Joe Biden
Luis Pena
Show more
16:05 31.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Retail and Consumer Goods
Startups & Entrepreneurship
CEO Changes
Financial Scams and Security
Banking Regulations
Global Financial Events
Finance Mergers & Acquisitions
Market Analysis and Predictions
Industry Mergers & Acquisitions
Central Bank Actions
Hedge Funds & Private Equity
Workplace Trends
Global Trade Developments
Supply Chain Management
Government Economic Policies
Corporate Social Responsibility
AI Innovations
Countries:
Companies:
Wells Fargo & Company
The Goldman Sachs Group, Inc.
Tesla, Inc.
Barclays PLC
Bank of America Corporation
NatWest Group plc
Apple Inc.
JPMorgan Chase & Co.
Lloyds Banking Group plc
Mastercard Inc
Visa Inc.
Santander UK plc
Morgan Stanley
Mercedes-Benz Group AG
Amazon.com, Inc.
OpenAI ERC USD
Tiktok USD
DoorDash, Inc.
Deliveroo plc
Nissan Motor Co., Ltd.
Currencies:
United States Dollar
Chinese Yuan
British Pound Sterling
Euro
Swiss Franc
Japanese Yen
Indonesian Rupiah
Indian Rupee
Offshore Chinese Yuan
United Arab Emirates Dirham
Singapore Dollar
Qatari Riyal
South Korean Won
Jordanian Dinar
Brazilian Real
People: